Evaluation of MDM2 Regulation on AURKB Expression and Cell Death in Lung Cancer
Abstract
This research examines the molecular mechanisms by which MDM2 regulates AURKB in lung cancer cells. In the United States alone nearly 238,340 people will be diagnosed with lung cancer in 2023. Hence, the need for new anti-cancer drugs and treatment methods is still persisting to fight against this deadly disease. This study explores the intracellular link between MDM2 and AURKB, to determine how manipulating this molecular mechanism can lead to cell cycle arrest and cancer cell death.
Lung cancer cells were treated with RG7388, an MDM2 inhibitor, and Barasertib, an AURKB inhibitor. Following treatments, the cells were lysed, and western blot analyses were carried out to determine the expression levels of MDM2, AURKB, FOXO3a, p53, p21, and Cyclin D. The lung cancer cells treated with the MDM2 inhibitors showed an increase in the levels of tumor suppressor genes. Additionally, drug-treated cancer cells also displayed an increase in the levels of genes that are known to cause cell death. According to the results obtained, RG7388 mediated inhibition of MDM2 results in a downregulation of AURKB expression. Additionally, downregulating AURKB seems to cause cancer cell death during our experiments. To better assess how RG3788 treatment affects lung cancer cells, more experiments will be done utilizing H460 and H446 lung cancer cells to determine how each cell line is affected by MDM2 and AURKB inhibitors.
Faculty Sponsors
Dr. Umamaheswari Natarajan, Dr. Mir Saleem, Dr. Appu Rathinavelu
Project Type
Event
Location
Alvin Sherman Library
Start Date
4-5-2023 12:00 PM
End Date
4-6-2023 4:00 PM
Evaluation of MDM2 Regulation on AURKB Expression and Cell Death in Lung Cancer
Alvin Sherman Library
This research examines the molecular mechanisms by which MDM2 regulates AURKB in lung cancer cells. In the United States alone nearly 238,340 people will be diagnosed with lung cancer in 2023. Hence, the need for new anti-cancer drugs and treatment methods is still persisting to fight against this deadly disease. This study explores the intracellular link between MDM2 and AURKB, to determine how manipulating this molecular mechanism can lead to cell cycle arrest and cancer cell death.
Lung cancer cells were treated with RG7388, an MDM2 inhibitor, and Barasertib, an AURKB inhibitor. Following treatments, the cells were lysed, and western blot analyses were carried out to determine the expression levels of MDM2, AURKB, FOXO3a, p53, p21, and Cyclin D. The lung cancer cells treated with the MDM2 inhibitors showed an increase in the levels of tumor suppressor genes. Additionally, drug-treated cancer cells also displayed an increase in the levels of genes that are known to cause cell death. According to the results obtained, RG7388 mediated inhibition of MDM2 results in a downregulation of AURKB expression. Additionally, downregulating AURKB seems to cause cancer cell death during our experiments. To better assess how RG3788 treatment affects lung cancer cells, more experiments will be done utilizing H460 and H446 lung cancer cells to determine how each cell line is affected by MDM2 and AURKB inhibitors.
